Trial
NCT03185481
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Pfizer
Collaborators
—
Condition
Parkinson's Disease With Motor Fluctuations
Intervention
1 mg QD to 15 mg QD PF-06649751
Why stopped
Terminated 25Sep17 due to parent study insufficient efficacy. Not due to safety
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-12